Clinical Trial Update: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lanreotide autogel/depot 120 mg vs placebo in lung neuroendocrine tumors; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neuroendocrine Tumor
• Neuroendocrine Tumor of the Lung

Drugs mentioned

• Lanreotide Autogel/Depot (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Neuroendocrine Tumors in Lung | Phase 3 | Status: TERMINATED | Results posted: 2021-10-29